Last updated: February 21, 2026
What is the Therapeutic Area and Market Position?
NDC 72603-0287 corresponds to Zuranolone (S AGE 546), a selective GABA-A receptor positive allosteric modulator developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). It is part of the neuroactive steroid class, aiming at rapid-onset antidepressant effects.
The drug is under development by Sage Therapeutics, targeting the large MDD and PPD markets, which have significant unmet medical needs.
Market Size and Growth Dynamics
Global depression treatment market size was valued at approximately USD 11 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8-10% from 2022 to 2030 [1]. The PPD segment specifically is estimated to reach USD 1.2 billion by 2027, driven by increasing awareness, diagnosis rates, and recent regulatory approvals for new therapies.
The market is driven by:
- High prevalence: Over 280 million globally suffer from MDD, with postpartum depression affecting 10-20% of women postpartum [2].
- Demand for rapid-acting medications: Traditional SSRIs take weeks to show effects, leading to growth in rapid-onset agents like Zuranolone.
- Regulatory incentives: Fast-track designations and breakthrough therapy designations enhance commercialization prospects.
Competitive Landscape
Key competitors include:
| Drug Name |
Class |
Status |
Marketed Since |
Notes |
| Brexanolone (Zulresso) |
Neuroactive steroid |
Approved (FDA, 2019) |
2019 |
IV formulation, high cost |
| Esketamine (Spravato) |
NMDA receptor antagonist |
Approved (FDA, 2019) |
2019 |
Nasal spray, high cost |
| SAGE-217 (Zuranolone) |
GABA-A modulator |
Pending approval (as of 2022) |
N/A |
Differentiates via oral administration |
The oral formulation of Zuranolone offers a significant advantage in ease of administration and potentially lower treatment costs.
Price Projections and Cost Analysis
Current Market Prices
- Brexanolone: Approximately USD 34,000 for a 60-hour infusion course [3].
- Spravato: Around USD 590 per nasal spray dose, with typical courses costing USD 26,000.
- Zuranolone: Expected to be priced lower due to oral administration and competitive positioning; projections estimate USD 3,000-5,000 per treatment course.
Price Drivers
Factors influencing Zuranolone’s eventual price include:
- Manufacturing costs: Oral agents generally exhibit reduced production expenses compared to infusion or nasal spray formulations.
- Regulatory status: FDA approval in late 2022 or 2023.
- Market penetration: Pivotal trials indicate a rapid onset of action, which could justify a premium price within current standards.
- Payer reimbursement: Insurance coverage will influence actual patient access.
Revenue Considerations
Assuming approval and initial market penetration reaching 30% of the PPD market (around 360,000 eligible patients globally) at an average treatment cost of USD 4,000 per course:
| Scenario |
Market Penetration |
Patients |
Total Revenue (USD) |
Comments |
| Base |
30% |
108,000 |
432 million |
Assumes full uptake in early phase |
| Optimistic |
50% |
180,000 |
720 million |
Long-term, expanded access, pricing adjustments |
Regulatory and Commercial Milestones
- FDA New Drug Application (NDA) submission was planned for late 2022.
- Orphan drug or breakthrough therapy designations may accelerate approval.
- Commercial launch expected in 2023-24, contingent on regulatory review.
Risks and Market Challenges
- Regulatory hurdles: Delays or rejections in approval processes.
- Competitive responses: Market entry of similar oral agents.
- Pricing pressures: Payers demanding lower prices for high-cost mental health therapies.
- Patient adoption: Acceptance of new oral agents over established treatments.
Key Takeaways
- The depression treatment market, especially for rapid-onset agents, is expanding rapidly.
- Zuranolone aims to fill a significant unmet need with an oral formulation expected to cost less per treatment than current options.
- Price projections suggest USD 3,000-5,000 per course, with potential for higher revenues if market penetration is achieved.
- Competitive landscape, regulatory status, and payer policies will shape the ultimate market size.
FAQs
Q1: When is Zuranolone expected to receive FDA approval?
A1: Initial filings were submitted in late 2022; approval anticipated in 2023 or early 2024.
Q2: How does Zuranolone differ from Brexanolone?
A2: Zuranolone is an oral agent, offering convenience over Brexanolone’s IV infusion, which requires hospitalization.
Q3: What are the main barriers to market entry?
A3: Regulatory approval delays, pricing negotiations, and competition from established therapies.
Q4: What is the potential global market size for Zuranolone?
A4: Estimated USD 1-2 billion in annual sales by 2025, considering global prevalence and treatment rates.
Q5: How will payer policies influence the drug’s market?
A5: Reimbursement decisions will depend on clinical efficacy demonstrations, cost-effectiveness, and comparative benefits over existing therapies.
References
[1] Statista. (2022). Depression treatment market size. https://www.statista.com
[2] WHO. (2021). Depression and other common mental disorders. https://www.who.int
[3] MarketWatch. (2021). Pricing of neuroactive steroid therapies. https://www.marketwatch.com
